Literature DB >> 8695029

Chymase-dependent angiotensin II forming systems in humans.

H Urata1, H Nishimura, D Ganten.   

Abstract

Recent studies have provided evidence that human cardiovascular tissues contain components of the renin angiotensin system: angiotensinogen, renin, angiotensin I converting enzyme (ACE), chymase, and angiotensin (Ang) II receptors. It is likely that locally produced Ang II plays an important role in cardiovascular homeostasis in autocrine and paracrine fashions and may also be involved in remodeling of the heart and vasculature in pathological conditions. In addition to ACE, a cardiac Ang II-forming serine proteinase (human heart chymase) has been identified in the left ventricle of the human heart. The different cellular and regional distribution of ACE and heart chymase in the heart as well as in blood vessels implies distinct pathophysiological roles of these two Ang II-forming enzymes. Several reports indicate that both ACE dependent and ACE independent Ang II formation appears to take place in hypoxic or ischemic heart or blood vessel in vivo and seems to be involved in their pathological changes. However, chymase dependent Ang II formation, chymostatin sensitive but aprotinin insensitive, does not explain all of ACE independent Ang II formation. Therefore, it has become quite important to clarify the detailed mechanisms of the tissue Ang II formation in humans and their contribution to the pathophysiological changes in cardiovascular diseases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8695029     DOI: 10.1016/0895-7061(95)00349-5

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  20 in total

1.  Angiotensin II: a major regulator of subcutaneous adipose tissue blood flow in humans.

Authors:  G H Goossens; S E McQuaid; A L Dennis; M A van Baak; E E Blaak; K N Frayn; W H M Saris; F Karpe
Journal:  J Physiol       Date:  2006-01-05       Impact factor: 5.182

2.  Review: Intrarenal angiotensin II levels in normal and hypertensive states.

Authors:  L Gabriel Navar; Kenneth D Mitchell; Lisa M Harrison-Bernard; Hiroyuki Kobori; Akira Nishiyama
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2001-03       Impact factor: 1.636

3.  Angiotensin II is involved in nitric oxide synthase and cyclo-oxygenase inhibition-induced leukocyte-endothelial cell interactions in vivo.

Authors:  A Alvarez; L Piqueras; R Bello; A Canet; L Moreno; P Kubes; M J Sanz
Journal:  Br J Pharmacol       Date:  2001-02       Impact factor: 8.739

4.  Renin released from mast cells activated by circulating MCP-1 initiates the microvascular phase of the systemic inflammation of alveolar hypoxia.

Authors:  Jie Chao; Gustavo Blanco; John G Wood; Norberto C Gonzalez
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-09-30       Impact factor: 4.733

5.  Chymase-dependent production of angiotensin II: an old enzyme in old hearts.

Authors:  Ghezal Froogh; John T Pinto; Yicong Le; Sharath Kandhi; Yeabsra Aleligne; An Huang; Dong Sun
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-11-04       Impact factor: 4.733

6.  Major role for ACE-independent intrarenal ANG II formation in type II diabetes.

Authors:  Sungmi Park; Benjamin J Bivona; Hiroyuki Kobori; Dale M Seth; Mark C Chappell; Eric Lazartigues; Lisa M Harrison-Bernard
Journal:  Am J Physiol Renal Physiol       Date:  2009-10-21

Review 7.  Role of aldosterone in the progression of chronic kidney disease and potential use of aldosterone blockade in children.

Authors:  Elaine Ku; Vito M Campese
Journal:  Pediatr Nephrol       Date:  2009-04-04       Impact factor: 3.714

Review 8.  The tissue renin-angiotensin-aldosterone system in diabetes mellitus.

Authors:  Donna S Hanes; Anita Nahar; Matthew R Weir
Journal:  Curr Hypertens Rep       Date:  2004-04       Impact factor: 5.369

9.  Characteristics of patients prescribed angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the combination at an urban medical center.

Authors:  Ghania Masri; Kristi Bledsoe; Carlos Palacio
Journal:  MedGenMed       Date:  2007-11-20

Review 10.  Cardiovascular effects of losartan and its relevant clinical application.

Authors:  Feichao Xu; Caiping Mao; Yali Hu; Can Rui; Zhice Xu; Lubo Zhang
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.